How GLP-1 Drugs Affect Cancer Risk: Evidence, Mechanisms, and Safety

https://www.news-medical.net/health/How-GLP-1-Drugs-Affect-Cancer-Risk-Evidence-Mechanisms-and-Safety.aspx Can metabolic treatments change cancer risk? Studies of GLP-1 receptor agonists examine how weight loss, insulin regulation, and tumor biology may intersect. Since their approval, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have improved management of metabolic conditions such as obesity and type 2 diabetes (T2D). Given the well-established association between weight loss and reduced cancer risk, researchers are investigating whether these drugs could also protect against cancer.